Igc Pharma Inc (IGC)

$0.31 -0.01 (-2.54%)
Market Cap 31.53M
Revenue (ttm) 1.27M
Net Income (ttm) -7.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -560.63%
Debt to Equity Ratio 0.02
Volume 447,600
Avg Vol 1,240,366
Day's Range N/A - N/A
Shares Out 98.80M
Stochastic %K 27%
Beta 0.50
Analysts Sell
Price Target $4.12

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MI...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 983 0998
Address:
10224 Falls Road, Potomac, United States
RocketQueen
RocketQueen May. 8 at 9:24 PM
$IGC double bottom on monthly time scales.
0 · Reply
RocketQueen
RocketQueen May. 8 at 4:06 AM
$IGC good video. They have two horses in the race... https://www.youtube.com/watch?v=rNLeeu3v6S4
0 · Reply
RocketQueen
RocketQueen May. 5 at 6:40 PM
$IGC in case you didn't see it, Ascendient Capital raised their price target up to 5.25. The catalyst could be full patient enrollment or upcoming phase II results.
1 · Reply
RocketQueen
RocketQueen May. 5 at 1:57 PM
$IGC we notice recent whale accumulation here. Expect potential for soaring prices by mid Summer time frame.
0 · Reply
RocketQueen
RocketQueen May. 4 at 6:35 PM
$IGC could rise to over several dollars with full patient enrollment this year.
1 · Reply
luminouslumens
luminouslumens May. 1 at 5:39 PM
$IGC 🧐
0 · Reply
RocketQueen
RocketQueen May. 1 at 2:49 PM
$IGC tail winds in play here soon.
0 · Reply
RoaringAlpha1
RoaringAlpha1 May. 1 at 3:12 AM
$ACB $AKAN $CGC $IGC $TCNNF
0 · Reply
StocktwitsNews
StocktwitsNews May. 1 at 3:08 AM
AKAN Stock Leaves Cannabis Peers In The Smoke With A Stunning 1,700% Rally In April — What’s Fueling The Run? $AKAN $TCNNF $CGC $IGC $ACB https://stocktwits.com/news/equity/markets/akan-stock-april-rally-leaves-cannabis-peers-behind/cZQNseyReIl
0 · Reply
Young_Bobby_Axel
Young_Bobby_Axel Apr. 30 at 3:57 PM
$IGC $SRXH slave contracts , 360 deals
0 · Reply
Latest News on IGC
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

Apr 28, 2026, 12:15 PM EDT - 10 days ago

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial

2026-04-22T13:29:55.000Z - 16 days ago

IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

Apr 22, 2026, 8:30 AM EDT - 17 days ago

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

IGC Pharma secures Colombian authorization for psilocybin research

2026-04-20T14:17:51.000Z - 18 days ago

IGC Pharma secures Colombian authorization for psilocybin research

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

Apr 20, 2026, 8:30 AM EDT - 19 days ago

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial

2026-04-14T12:36:26.000Z - 25 days ago

IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

Apr 14, 2026, 8:30 AM EDT - 25 days ago

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

Apr 8, 2026, 12:45 PM EDT - 4 weeks ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

IGC announces activation of new clinical trial sate for Phase 2 CALMA trial

2026-04-07T12:50:45.000Z - 4 weeks ago

IGC announces activation of new clinical trial sate for Phase 2 CALMA trial

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

Apr 7, 2026, 8:00 AM EDT - 4 weeks ago

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

IGC Pharma enters national media partnership with New to The Street

2026-03-30T12:38:30.000Z - 5 weeks ago

IGC Pharma enters national media partnership with New to The Street

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

Mar 30, 2026, 8:00 AM EDT - 5 weeks ago

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

IGC Pharma, New to The Street launch 12-part national media partnership

2026-03-25T12:20:15.000Z - 6 weeks ago

IGC Pharma, New to The Street launch 12-part national media partnership

IGC Pharma reports 9-month revenue $969K

2026-03-19T13:12:05.000Z - 7 weeks ago

IGC Pharma reports 9-month revenue $969K

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

Mar 19, 2026, 9:00 AM EDT - 7 weeks ago

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

IGC Pharma to showcase AI platform with ADDI at ADPD 2026

2026-03-18T13:10:59.000Z - 7 weeks ago

IGC Pharma to showcase AI platform with ADDI at ADPD 2026

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

Mar 18, 2026, 9:00 AM EDT - 7 weeks ago

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

IGC Pharma files utility patent applications covering AHA framework

2026-02-26T13:49:48.000Z - 2 months ago

IGC Pharma files utility patent applications covering AHA framework

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

Feb 26, 2026, 8:30 AM EST - 2 months ago

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

Feb 24, 2026, 8:30 AM EST - 2 months ago

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

IGC Pharma expands Phase 2 CALMA trial with new clinical site

2026-02-23T13:49:20.000Z - 2 months ago

IGC Pharma expands Phase 2 CALMA trial with new clinical site

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

Feb 23, 2026, 8:30 AM EST - 2 months ago

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

IGC Pharma Transcript: Status update

Feb 18, 2026, 1:00 PM EST - 2 months ago

IGC Pharma Transcript: Status update

IGC Pharma issued notice of allowance by CIPO for IGC-AD1

2026-02-17T13:52:12.000Z - 2 months ago

IGC Pharma issued notice of allowance by CIPO for IGC-AD1

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

Feb 17, 2026, 8:30 AM EST - 2 months ago

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

Feb 12, 2026, 8:30 AM EST - 3 months ago

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

IGC Pharma Announces Equity Research Update by Alliance Global Partners

Feb 10, 2026, 8:30 AM EST - 3 months ago

IGC Pharma Announces Equity Research Update by Alliance Global Partners

IGC Pharma expands Phase 2 CALMA trial with new clinical site

2026-02-09T14:01:42.000Z - 3 months ago

IGC Pharma expands Phase 2 CALMA trial with new clinical site

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

Feb 9, 2026, 8:30 AM EST - 3 months ago

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

IGC Pharma reaches 70% enrollment in Phase 2 CALMA trial of IGC-AD1

2026-02-02T14:01:51.000Z - 3 months ago

IGC Pharma reaches 70% enrollment in Phase 2 CALMA trial of IGC-AD1

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

Feb 2, 2026, 8:30 AM EST - 3 months ago

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

IGC Pharma expands Phase 2 CALMA trial with new clinical site

2026-01-22T14:11:10.000Z - 3 months ago

IGC Pharma expands Phase 2 CALMA trial with new clinical site

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

Jan 22, 2026, 9:00 AM EST - 3 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Jan 12, 2026, 9:00 AM EST - 4 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

Jan 6, 2026, 8:00 AM EST - 4 months ago

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Jan 5, 2026, 9:00 AM EST - 4 months ago

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 19, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 15, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 10, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 9, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Dec 2, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 25, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

IGC Pharma Earnings Call Transcript: Q2 2026

Nov 17, 2025, 11:00 AM EST - 6 months ago

IGC Pharma Earnings Call Transcript: Q2 2026

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 17, 2025, 8:30 AM EST - 6 months ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 13, 2025, 9:00 AM EST - 6 months ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 10, 2025, 9:00 AM EST - 6 months ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Nov 3, 2025, 8:52 AM EST - 6 months ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 22, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 14, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 10, 2025, 7:50 PM EDT - 7 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Oct 7, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 29, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 24, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 22, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 9, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Sep 2, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 28, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 27, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 25, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 19, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 12, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Aug 5, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 23, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 21, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jul 10, 2025, 3:10 PM EDT - 10 months ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

IGC Pharma Earnings Call Transcript: Q4 2025

Jun 30, 2025, 11:00 AM EDT - 11 months ago

IGC Pharma Earnings Call Transcript: Q4 2025

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 30, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

RocketQueen
RocketQueen May. 8 at 9:24 PM
$IGC double bottom on monthly time scales.
0 · Reply
RocketQueen
RocketQueen May. 8 at 4:06 AM
$IGC good video. They have two horses in the race... https://www.youtube.com/watch?v=rNLeeu3v6S4
0 · Reply
RocketQueen
RocketQueen May. 5 at 6:40 PM
$IGC in case you didn't see it, Ascendient Capital raised their price target up to 5.25. The catalyst could be full patient enrollment or upcoming phase II results.
1 · Reply
RocketQueen
RocketQueen May. 5 at 1:57 PM
$IGC we notice recent whale accumulation here. Expect potential for soaring prices by mid Summer time frame.
0 · Reply
RocketQueen
RocketQueen May. 4 at 6:35 PM
$IGC could rise to over several dollars with full patient enrollment this year.
1 · Reply
luminouslumens
luminouslumens May. 1 at 5:39 PM
$IGC 🧐
0 · Reply
RocketQueen
RocketQueen May. 1 at 2:49 PM
$IGC tail winds in play here soon.
0 · Reply
RoaringAlpha1
RoaringAlpha1 May. 1 at 3:12 AM
$ACB $AKAN $CGC $IGC $TCNNF
0 · Reply
StocktwitsNews
StocktwitsNews May. 1 at 3:08 AM
AKAN Stock Leaves Cannabis Peers In The Smoke With A Stunning 1,700% Rally In April — What’s Fueling The Run? $AKAN $TCNNF $CGC $IGC $ACB https://stocktwits.com/news/equity/markets/akan-stock-april-rally-leaves-cannabis-peers-behind/cZQNseyReIl
0 · Reply
Young_Bobby_Axel
Young_Bobby_Axel Apr. 30 at 3:57 PM
$IGC $SRXH slave contracts , 360 deals
0 · Reply
witdagame
witdagame Apr. 30 at 3:52 PM
$SRXH $IGC holding these two Pennie’s with massive potential
0 · Reply
RocketQueen
RocketQueen Apr. 29 at 3:15 PM
$IGC completion of patient enrollment could send this soaring...I agree that the ingredients they are using is likely to work at achieving its objective at relieving agitation and inducing calm.
0 · Reply
RocketQueen
RocketQueen Apr. 28 at 11:06 PM
$IGC unusual options price activity in the 5.00 USD strike range here.
1 · Reply
focafoca99
focafoca99 Apr. 28 at 9:39 PM
$IGC advanced caregiver engagement as its Phase 2 CALMA trial moved into the final enrollment phase. https://www.rapidticker.com/news/igc-igc-pharma-advances-caregiver-engagement-f5efa2
0 · Reply
MaskMaker
MaskMaker Apr. 28 at 1:03 AM
$QTI $IGC $ICU $NXL
0 · Reply
RocketQueen
RocketQueen Apr. 27 at 10:46 PM
$IGC has not started making the big moves yet.
1 · Reply
MaskMaker
MaskMaker Apr. 27 at 8:21 PM
$APCX $IGC $MPU $NXL $VTGN
0 · Reply
_AU79_
_AU79_ Apr. 27 at 8:14 PM
$IGC come on IGC let’s see the move!
0 · Reply
RocketQueen
RocketQueen Apr. 27 at 3:18 PM
$IGC average PT is over 4.00 USD...
0 · Reply
RocketQueen
RocketQueen Apr. 25 at 1:39 AM
$IGC this is really going to blow upward soon.
0 · Reply
Young_Bobby_Axel
Young_Bobby_Axel Apr. 24 at 4:24 PM
$IGC
0 · Reply
MaskMaker
MaskMaker Apr. 23 at 11:23 PM
$APCX $IGC $MPU $NXL $VTGN
0 · Reply